Sionna Therapeutics Slashes Workforce to Fund Cystic Fibrosis Trials

Facing a pivot in its clinical pipeline, Sionna Therapeutics announced a 46% reduction in its workforce this Monday. The biotech firm aims to concentrate its dwindling resources on a dual-drug combination therapy for cystic fibrosis, effectively buying itself a cash runway that extends into late 2029.

Today, 10:16· Money Talk· 364 reads

The company intends to prioritize the development of its SION-451 and SION-2222 combination, moving the candidates toward a phase 2a proof-of-concept trial. To fund this shift, management is halting investment in other pipeline assets. This restructuring will cost approximately $6.4 million, with the bulk of the layoffs finalized by the end of the third quarter.

Sionna expects the phase 2a trial to commence in the first quarter of 2027. Despite the promise of a longer financial horizon, investors reacted with caution, sending shares down 4% to $7.93 in after-hours trading.

Sionna Therapeutics Slashes Workforce to Fund Cystic Fibrosis Trials

Comments (0)